IL289596A - Trans-cyclooctane bioorthogonal materials and uses in cancer and immunotherapy - Google Patents
Trans-cyclooctane bioorthogonal materials and uses in cancer and immunotherapyInfo
- Publication number
- IL289596A IL289596A IL289596A IL28959622A IL289596A IL 289596 A IL289596 A IL 289596A IL 289596 A IL289596 A IL 289596A IL 28959622 A IL28959622 A IL 28959622A IL 289596 A IL289596 A IL 289596A
- Authority
- IL
- Israel
- Prior art keywords
- bioorthogonal
- cyclooctene
- immunotherapy
- trans
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
- URYYVOIYTNXXBN-OWOJBTEDSA-N trans-cyclooctene Chemical compound C1CCC\C=C\CC1 URYYVOIYTNXXBN-OWOJBTEDSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Materials Engineering (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962871051P | 2019-07-05 | 2019-07-05 | |
| US202062971196P | 2020-02-06 | 2020-02-06 | |
| US202062981401P | 2020-02-25 | 2020-02-25 | |
| PCT/US2020/040891 WO2021007160A1 (en) | 2019-07-05 | 2020-07-06 | Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL289596A true IL289596A (en) | 2022-03-01 |
Family
ID=71842858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL289596A IL289596A (en) | 2019-07-05 | 2022-01-03 | Trans-cyclooctane bioorthogonal materials and uses in cancer and immunotherapy |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220259254A1 (https=) |
| EP (1) | EP3993834A1 (https=) |
| JP (2) | JP7622031B2 (https=) |
| CN (1) | CN114340680A (https=) |
| AU (1) | AU2020310853A1 (https=) |
| CA (1) | CA3145889A1 (https=) |
| IL (1) | IL289596A (https=) |
| WO (1) | WO2021007160A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116056765A (zh) | 2020-08-07 | 2023-05-02 | 坦伯公司 | 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途 |
| WO2023077129A1 (en) | 2021-10-29 | 2023-05-04 | Tambo, Inc. | Tetrazine conjugates for in vivo targeted delivery of a payload |
| CN121419788A (zh) | 2023-05-04 | 2026-01-27 | 坦博公司 | 用于体内递送有效载荷的基于四嗪的靶向剂 |
| EP4713022A1 (en) | 2023-05-18 | 2026-03-25 | Tambo, Inc. | Trans-cyclooctene-modified targeted protein degrader conjugates |
| KR20260046464A (ko) * | 2023-07-27 | 2026-04-07 | 베락사 바이오테크 게엠베하 | 친수성 트랜스-시클로옥텐(hyTCO) 화합물, 이를 포함하는 구조체 및 접합체 |
| WO2025059685A1 (en) | 2023-09-15 | 2025-03-20 | Tambo, Inc. | Methods for in vivo targeted delivery of a payload |
| CN117599001B (zh) * | 2023-11-29 | 2025-05-09 | 南京鼓楼医院 | 一种生物正交Janus微球及其制备方法和应用 |
| CN119424649A (zh) * | 2024-02-29 | 2025-02-14 | 中山大学附属第一医院 | 假体周围感染治疗靶点及其应用 |
| WO2025231424A1 (en) * | 2024-05-02 | 2025-11-06 | Arizona Board Of Regents On Behalf Of Arizona State University | Procapped mrna for targeted cell translation |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| US7919079B2 (en) | 2006-03-31 | 2011-04-05 | Biosante Pharmaceuticals, Inc. | Cancer immunotherapy compositions and methods of use |
| EP2017281A4 (en) | 2006-04-14 | 2012-03-14 | Kyowa Hakko Kirin Co Ltd | AGONISTS AT TOLL-LIKE RECEPTOR 9 |
| KR20100053598A (ko) | 2007-08-01 | 2010-05-20 | 이데라 파마슈티칼즈, 인코포레이티드 | Ｔｌｒ９의 신규한 합성 효능제 |
| EP2391718A2 (en) | 2009-01-30 | 2011-12-07 | Idera Pharmaceuticals, Inc. | Novel synthetic agonists of tlr9 |
| EP3195868A3 (en) * | 2010-10-01 | 2017-08-02 | VentiRx Pharmaceuticals, Inc. | Therapeutic use of a tlr agonist and combination therapy |
| US20150297741A1 (en) * | 2012-11-22 | 2015-10-22 | Tagworks Pharmaceuticals B.V. | Bio-orthogonal drug activation |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| WO2014189806A1 (en) | 2013-05-18 | 2014-11-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| ES2966631T3 (es) | 2013-06-19 | 2024-04-23 | Univ California | Estructuras químicas para el suministro localizado de agentes terapéuticos |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| JP2016538344A (ja) | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 癌処置としてのｓｔｉｎｇアゴニストの使用 |
| HUE045065T2 (hu) | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| CN106659796B (zh) | 2014-03-14 | 2021-04-30 | 加利福尼亚大学董事会 | Tco缀合物和治疗剂递送方法 |
| CR20160564A (es) | 2014-06-04 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Dinucleótidos cíclicos como moduladores de sting |
| GB201501462D0 (en) | 2015-01-29 | 2015-03-18 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| EA035817B1 (ru) | 2015-03-10 | 2020-08-14 | Адуро Байотек, Инк. | Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона" |
| KR102779525B1 (ko) | 2015-05-29 | 2025-03-12 | 다이나박스 테크놀로지 코퍼레이션 | 폐암을 치료하기 위한 폴리뉴클레오티드 Toll-유사 수용체 9 아고니스트의 폐내 투여 |
| US10532056B2 (en) * | 2015-06-29 | 2020-01-14 | Verastem, Inc. | Therapeutic compositions, combinations, and methods of use |
| KR102222186B1 (ko) | 2015-08-13 | 2021-03-03 | 머크 샤프 앤드 돔 코포레이션 | Sting 효능제로서 시클릭 디-뉴클레오티드 화합물 |
| WO2017044983A1 (en) * | 2015-09-10 | 2017-03-16 | Shasqi, Inc. | Bioorthogonal compositions |
| JP2018534295A (ja) | 2015-10-28 | 2018-11-22 | アドゥロ バイオテック，インク． | 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法 |
| CN107849084B (zh) | 2015-12-03 | 2021-09-14 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为sting调节剂的环状嘌呤二核苷酸 |
| KR102789862B1 (ko) | 2016-01-11 | 2025-04-03 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드 |
| NZ746112A (en) | 2016-03-18 | 2023-01-27 | Immune Sensor Llc | Cyclic di-nucleotide compounds and methods of use |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| IL264049B2 (en) | 2016-07-06 | 2023-11-01 | Sperovie Biosciences Inc | Compounds, preparations and methods for treating the disease |
| WO2018009652A1 (en) | 2016-07-06 | 2018-01-11 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| CN109715202A (zh) | 2016-07-15 | 2019-05-03 | 斯必乐维生物科学公司 | 用于治疗疾病的化合物、组合物和方法 |
| WO2018013887A1 (en) | 2016-07-15 | 2018-01-18 | Sperovie Biosciences, Inc. | Compounds, compositions, and methods for the treatment of disease |
| CN109790220A (zh) | 2016-08-25 | 2019-05-21 | 豪夫迈·罗氏有限公司 | 与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药 |
| US10537590B2 (en) | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
| PT3523287T (pt) | 2016-10-04 | 2021-10-06 | Merck Sharp & Dohme | Compostos de benzo[b]tiofeno como agonistas de sting |
| EP3532505A4 (en) | 2016-10-25 | 2019-12-25 | Urogen Pharma Ltd. | BODY CAVES IMMUNODULATING TREATMENTS |
| JOP20170188A1 (ar) | 2016-11-25 | 2019-01-30 | Janssen Biotech Inc | ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting) |
| PE20210255A1 (es) | 2016-12-01 | 2021-02-10 | Takeda Pharmaceuticals Co | Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon) |
| AU2017378782A1 (en) | 2016-12-20 | 2019-07-04 | Merck Sharp & Dohme Corp. | Combinations of PD-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
| WO2018118665A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Cyclic dinucleotide sting agonists for cancer treatment |
| US11021511B2 (en) | 2017-01-27 | 2021-06-01 | Janssen Biotech, Inc. | Cyclic dinucleotides as sting agonists |
| CN110234403A (zh) | 2017-01-27 | 2019-09-13 | 詹森生物科技公司 | 作为sting激动剂的环状二核苷酸 |
| JOP20190218A1 (ar) | 2017-03-22 | 2019-09-22 | Boehringer Ingelheim Int | مركبات ثنائية النيوكليوتيدات حلقية معدلة |
| AU2018250312C1 (en) * | 2017-04-07 | 2024-08-22 | Tambo, Inc. | Bioorthogonal compositions |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| US20200138827A1 (en) | 2017-06-22 | 2020-05-07 | Curadev Pharma Limited | Small molecule modulators of human sting |
| UA125730C2 (uk) | 2017-06-22 | 2022-05-25 | Курадев Фарма Лімітед | Низькомолекулярні модулятори sting людини |
| WO2018234807A1 (en) | 2017-06-22 | 2018-12-27 | Curadev Pharma Limited | Heterocyclic small molecule modulators of human sting |
| JP2020530838A (ja) | 2017-08-04 | 2020-10-29 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト |
| WO2019046511A1 (en) | 2017-08-31 | 2019-03-07 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE |
| US11584774B2 (en) | 2017-09-11 | 2023-02-21 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| US11707531B2 (en) | 2017-09-11 | 2023-07-25 | F-star Therapeutics, Inc. | Compounds, compositions, and methods for the treatment of disease |
| AR114990A1 (es) | 2017-11-02 | 2020-11-18 | Alios Biopharma Inc | Constructos de oligonucleótidos y usos de los mismos |
| KR20200098511A (ko) | 2017-11-10 | 2020-08-20 | 다케다 야쿠힌 고교 가부시키가이샤 | Sting 조절제 화합물, 및 제조 및 사용 방법 |
| CN111712509A (zh) | 2017-12-15 | 2020-09-25 | 詹森生物科技公司 | 作为sting激动剂的环状二核苷酸 |
| CR20200260A (es) | 2017-12-15 | 2020-08-01 | Bayer Animal Health Gmbh | Composiciones inmunoestimulantes |
| US20190185509A1 (en) | 2017-12-20 | 2019-06-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'2' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| EP3727401A4 (en) | 2017-12-20 | 2022-04-06 | Merck Sharp & Dohme Corp. | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS |
| EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
-
2020
- 2020-07-06 WO PCT/US2020/040891 patent/WO2021007160A1/en not_active Ceased
- 2020-07-06 CA CA3145889A patent/CA3145889A1/en active Pending
- 2020-07-06 EP EP20747277.0A patent/EP3993834A1/en active Pending
- 2020-07-06 JP JP2022500512A patent/JP7622031B2/ja active Active
- 2020-07-06 AU AU2020310853A patent/AU2020310853A1/en active Pending
- 2020-07-06 US US17/624,625 patent/US20220259254A1/en active Pending
- 2020-07-06 CN CN202080049756.9A patent/CN114340680A/zh active Pending
-
2022
- 2022-01-03 IL IL289596A patent/IL289596A/en unknown
-
2025
- 2025-01-15 JP JP2025005471A patent/JP2025063195A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7622031B2 (ja) | 2025-01-27 |
| JP2022538690A (ja) | 2022-09-05 |
| AU2020310853A1 (en) | 2022-01-27 |
| EP3993834A1 (en) | 2022-05-11 |
| JP2025063195A (ja) | 2025-04-15 |
| WO2021007160A1 (en) | 2021-01-14 |
| CN114340680A (zh) | 2022-04-12 |
| US20220259254A1 (en) | 2022-08-18 |
| CA3145889A1 (en) | 2021-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289596A (en) | Trans-cyclooctane bioorthogonal materials and uses in cancer and immunotherapy | |
| PH12021550152A1 (en) | Anti-cd112r compositions and methods | |
| IL289866A (en) | Sting antibody-agonist conjugates and their use in immunotherapy | |
| ZA201800513B (en) | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | |
| IL286183A (en) | Using catequentinib (anlotinib) combining with standard chemotherapy or immunotherapy in sequential order for the cancer treatment | |
| IL276987A (en) | Peptides and combinations of peptides of non-canonical origin for immunotherapy against various cancers | |
| SG10202107869QA (en) | Peptides and combination thereof for use in the immunotherapy against cancers | |
| GB201511792D0 (en) | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers | |
| GB201604458D0 (en) | Peptides and combination of peptides for use in immunotherapy against cancers | |
| GB201504502D0 (en) | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers | |
| PL3624837T3 (pl) | Przeciwciała anty-fgfr2 w połączeniu ze środkami chemioterapeutycznymi w leczeniu nowotworu | |
| SG11202101924QA (en) | B*44 restricted peptides for use in immunotherapy against cancers and related methods | |
| IL274122A (en) | Antibody-antidrug-tissue factor conjugates and their use in cancer treatment | |
| SG11202106067UA (en) | Tubulysins and protein-tubulysin conjugates | |
| SG11202009659XA (en) | A*03 restricted peptides for use in immunotherapy against cancers and related methods | |
| SG10202100324YA (en) | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers | |
| SG11202009442YA (en) | Peptides for use in immunotherapy against cancers | |
| SG10202008013TA (en) | Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers | |
| HK40068345A (en) | Antibody-sting agonist conjugates and their use in immunotherapy | |
| HK40048502A (en) | B*44 restricted peptides for use in immunotherapy against cancers and related methods | |
| HK40022921A (en) | Peptides and combination thereof for use in the immunotherapy against cancers | |
| HK40017194A (en) | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers | |
| AU2019343184A1 (en) | Compositions and methods for treating cancer with anti-CD123 immunotherapy | |
| HK40039631A (en) | Peptides for use in immunotherapy against cancers | |
| HK40036590A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer |